[go: up one dir, main page]

WO2026013218A1 - Vecteurs anti-tdp-43, molécules de liaison et leurs utilisations - Google Patents

Vecteurs anti-tdp-43, molécules de liaison et leurs utilisations

Info

Publication number
WO2026013218A1
WO2026013218A1 PCT/EP2025/069818 EP2025069818W WO2026013218A1 WO 2026013218 A1 WO2026013218 A1 WO 2026013218A1 EP 2025069818 W EP2025069818 W EP 2025069818W WO 2026013218 A1 WO2026013218 A1 WO 2026013218A1
Authority
WO
WIPO (PCT)
Prior art keywords
seq
amino acid
tdp
acid sequence
chain variable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/EP2025/069818
Other languages
English (en)
Inventor
Elodie CHEVALIER
Tariq AFROZ
Mickaël Marc Pascal AUDRAIN
Florence GAUYE
Romain Christian OLLIER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AC Immune SA
Original Assignee
AC Immune SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AC Immune SA filed Critical AC Immune SA
Publication of WO2026013218A1 publication Critical patent/WO2026013218A1/fr
Pending legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Psychiatry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention se rapporte au domaine des protéines de liaison à l'ADN à réponse transactive qui ont un poids moléculaire de 43 kDa (TARDB ou également TDP-43). L'invention concerne des molécules de liaison spécifiques de TDP-43, en particulier des anticorps anti-TDP-43 ou des fragments de liaison à l'antigène ou un dérivé de ceux-ci, des vecteurs délivrant des anticorps de codage d'acide nucléique de l'invention, et leurs utilisations. La présente invention concerne des moyens et des méthodes pour diagnostiquer, prévenir, soulager et/ou traiter une maladie, un trouble et/ou une anomalie associé à des agrégats de TDP-43 comprenant sans s'y limiter la démence frontotemporale (FTD), la sclérose latérale amyotrophique (ALS), la maladie d'Alzheimer (AD), la maladie de Parkinson (PD), l'encéphalopathie traumatique chronique (CTE), et l'encéphalopathie TDP-43 à prédominance limbique liée à l'âge (LATE).
PCT/EP2025/069818 2024-07-10 2025-07-10 Vecteurs anti-tdp-43, molécules de liaison et leurs utilisations Pending WO2026013218A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP24187869 2024-07-10
EP24187869.3 2024-07-10

Publications (1)

Publication Number Publication Date
WO2026013218A1 true WO2026013218A1 (fr) 2026-01-15

Family

ID=91924244

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2025/069818 Pending WO2026013218A1 (fr) 2024-07-10 2025-07-10 Vecteurs anti-tdp-43, molécules de liaison et leurs utilisations

Country Status (1)

Country Link
WO (1) WO2026013218A1 (fr)

Citations (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5004697A (en) 1987-08-17 1991-04-02 Univ. Of Ca Cationized antibodies for delivery through the blood-brain barrier
US5112596A (en) 1990-04-23 1992-05-12 Alkermes, Inc. Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5268164A (en) 1990-04-23 1993-12-07 Alkermes, Inc. Increasing blood-brain barrier permeability with permeabilizer peptides
WO1995001937A1 (fr) 1993-07-09 1995-01-19 Association Gradient Procede de traitement de residus de combustion et installation de mise en ×uvre dudit procede
US5403484A (en) 1988-09-02 1995-04-04 Protein Engineering Corporation Viruses expressing chimeric binding proteins
US5500362A (en) 1987-01-08 1996-03-19 Xoma Corporation Chimeric antibody with specificity to human B cell surface antigen
US5624821A (en) 1987-03-18 1997-04-29 Scotgen Biopharmaceuticals Incorporated Antibodies with altered effector functions
US5648237A (en) 1991-09-19 1997-07-15 Genentech, Inc. Expression of functional antibody fragments
WO1997030087A1 (fr) 1996-02-16 1997-08-21 Glaxo Group Limited Preparation d'anticorps glycosyles
US5693761A (en) 1988-12-28 1997-12-02 Protein Design Labs, Inc. Polynucleotides encoding improved humanized immunoglobulins
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5821337A (en) 1991-06-14 1998-10-13 Genentech, Inc. Immunoglobulin variants
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
WO1998058964A1 (fr) 1997-06-24 1998-12-30 Genentech, Inc. Procedes et compositions concernant des glycoproteines galactosylees
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5885793A (en) 1991-12-02 1999-03-23 Medical Research Council Production of anti-self antibodies from antibody segment repertoires and displayed on phage
WO1999022764A1 (fr) 1997-10-31 1999-05-14 Genentech, Inc. Compositions renfermant des glycoformes de glycoproteine et methodes afferentes
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US5969108A (en) 1990-07-10 1999-10-19 Medical Research Council Methods for producing members of specific binding pairs
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
WO2000061739A1 (fr) 1999-04-09 2000-10-19 Kyowa Hakko Kogyo Co., Ltd. Methode de regulation de l'activite d'une molecule immunologiquement fonctionnelle
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
WO2001029246A1 (fr) 1999-10-19 2001-04-26 Kyowa Hakko Kogyo Co., Ltd. Procede de production d'un polypeptide
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US20020025313A1 (en) 1992-07-27 2002-02-28 Micklus Michael J. Targeting of liposomes to the blood-brain barrier
WO2002020565A2 (fr) 2000-09-08 2002-03-14 Universität Zürich Groupes de proteines a domaines de repetition comprenant des modules de repetition
US20020038086A1 (en) 2000-07-27 2002-03-28 Hynynen Kullervo H. Blood-brain barrier opening
WO2002031140A1 (fr) 2000-10-06 2002-04-18 Kyowa Hakko Kogyo Co., Ltd. Cellules produisant des compositions d'anticorps
WO2002032925A2 (fr) 2000-10-16 2002-04-25 Phylos, Inc. Echafaudages proteiniques internes pour analogues d'anticorps et autres proteines de liaison
US20020065259A1 (en) 2000-08-30 2002-05-30 Schatzberg Alan F. Glucocorticoid blocking agents for increasing blood-brain barrier permeability
US6420548B1 (en) 1999-10-04 2002-07-16 Medicago Inc. Method for regulating transcription of foreign genes
US20020164328A1 (en) 2000-10-06 2002-11-07 Toyohide Shinkawa Process for purifying antibody
WO2003011878A2 (fr) 2001-08-03 2003-02-13 Glycart Biotechnology Ag Variants de glycosylation d'anticorps presentant une cytotoxicite cellulaire accrue dependante des anticorps
US20030073713A1 (en) 2000-10-30 2003-04-17 Schoenhard Grant L. Inhibitors of ABC drug transporters at the blood-brain barrier
US20030115614A1 (en) 2000-10-06 2003-06-19 Yutaka Kanda Antibody composition-producing cell
US6602684B1 (en) 1998-04-20 2003-08-05 Glycart Biotechnology Ag Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
US20030157108A1 (en) 2001-10-25 2003-08-21 Genentech, Inc. Glycoprotein compositions
US20030162695A1 (en) 2002-02-27 2003-08-28 Schatzberg Alan F. Glucocorticoid blocking agents for increasing blood-brain barrier permeability
WO2003085119A1 (fr) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Procede d'amelioration de l'activite d'une composition d'anticorps de liaison avec le recepteur fc$g(g) iiia
WO2003085107A1 (fr) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Cellules à génome modifié
WO2003084570A1 (fr) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Medicament contenant une composition d'anticorps appropriee au patient souffrant de polymorphisme fc$g(g)riiia
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
WO2004044011A2 (fr) 2002-11-06 2004-05-27 Avidia Research Institute Bibliotheques combinatoires de domaines de monomere
US20040110282A1 (en) 2002-04-09 2004-06-10 Kyowa Hakko Kogyo Co., Ltd. Cells in which activity of the protein involved in transportation of GDP-fucose is reduced or lost
US20040109865A1 (en) 2002-04-09 2004-06-10 Kyowa Hakko Kogyo Co., Ltd. Antibody composition-containing medicament
WO2004056312A2 (fr) 2002-12-16 2004-07-08 Genentech, Inc. Variants d'immunoglobuline et utilisations
US20040131692A1 (en) 2001-05-05 2004-07-08 Joerg Kreuter Nanoparticles made of protein with coupled apolipoprotein e for penetration of the blood-brain barrier and methods for the production thereof
US20040132140A1 (en) 2002-04-09 2004-07-08 Kyowa Hakko Kogyo Co., Ltd. Production process for antibody composition
US20040204354A1 (en) 2002-12-03 2004-10-14 Thomas Nelson Artificial low-density lipoprotein carriers for transport of substances across the blood-brain barrier
WO2005035586A1 (fr) 2003-10-08 2005-04-21 Kyowa Hakko Kogyo Co., Ltd. Composition proteique hybride
WO2005035778A1 (fr) 2003-10-09 2005-04-21 Kyowa Hakko Kogyo Co., Ltd. Procede permettant de produire une composition d'anticorps par inhibition par l'arn de la fonction de $g(a)1,6-fucosyltransferase
US20050089473A1 (en) 2003-09-10 2005-04-28 Cedars-Sinai Medical Center Potassium channel mediated delivery of agents through the blood-brain barrier
WO2005040229A2 (fr) 2003-10-24 2005-05-06 Avidia, Inc. Multimeres et monomeres comprenant des domaines de recepteur de lipoproteines de basse densite de classe a et egf
US20050123546A1 (en) 2003-11-05 2005-06-09 Glycart Biotechnology Ag Antigen binding molecules with increased Fc receptor binding affinity and effector function
WO2005053742A1 (fr) 2003-12-04 2005-06-16 Kyowa Hakko Kogyo Co., Ltd. Medicament contenant une composition a base d'anticorps
WO2005100402A1 (fr) 2004-04-13 2005-10-27 F.Hoffmann-La Roche Ag Anticorps anti-p-selectine
US20050260186A1 (en) 2003-03-05 2005-11-24 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
WO2006029879A2 (fr) 2004-09-17 2006-03-23 F.Hoffmann-La Roche Ag Anticorps anti-ox40l
WO2006044908A2 (fr) 2004-10-20 2006-04-27 Genentech, Inc. Formulations d'anticorps
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
US7129084B2 (en) 2000-08-03 2006-10-31 Therapeutic Human Polyclonals, Inc. Production of humanized antibodies in transgenic animals
US7371826B2 (en) 1999-01-15 2008-05-13 Genentech, Inc. Polypeptide variants with altered effector function
WO2008077546A1 (fr) 2006-12-22 2008-07-03 F. Hoffmann-La Roche Ag Anticorps contre le récepteur du facteur de croissance i de type insuline et leurs utilisations
US7521541B2 (en) 2004-09-23 2009-04-21 Genetech Inc. Cysteine engineered antibodies and conjugates
WO2012020124A1 (fr) 2010-08-12 2012-02-16 Ac Immune S.A. Vaccin obtenu par génie génétique
WO2012055933A1 (fr) 2010-10-26 2012-05-03 Ac Immune S.A. Préparation d'un produit de recombinaison antigénique
WO2013061163A2 (fr) 2011-10-28 2013-05-02 Biogen Idec International Neuroscience Gmbh Molécules de liaison spécifiques de tdp-43
WO2013135588A1 (fr) 2012-03-16 2013-09-19 Covagen Ag Nouvelles molécules de liaison à activité antinéoplasique
WO2019134981A1 (fr) 2018-01-05 2019-07-11 Ac Immune Sa Molécules de liaison de tdp-43 mal-repliées
WO2020234473A1 (fr) 2019-05-23 2020-11-26 Ac Immune Sa Molécules de liaison anti-tdp-43 et leurs utilisations
US20230322908A1 (en) * 2020-08-14 2023-10-12 Ac Immune Sa Humanized Anti-TDP-43 Binding Molecules and Uses Thereof
WO2023194565A1 (fr) * 2022-04-08 2023-10-12 Ac Immune Sa Molécules de liaison anti-tdp-43

Patent Citations (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5500362A (en) 1987-01-08 1996-03-19 Xoma Corporation Chimeric antibody with specificity to human B cell surface antigen
US5648260A (en) 1987-03-18 1997-07-15 Scotgen Biopharmaceuticals Incorporated DNA encoding antibodies with altered effector functions
US5624821A (en) 1987-03-18 1997-04-29 Scotgen Biopharmaceuticals Incorporated Antibodies with altered effector functions
US5004697A (en) 1987-08-17 1991-04-02 Univ. Of Ca Cationized antibodies for delivery through the blood-brain barrier
US5403484A (en) 1988-09-02 1995-04-04 Protein Engineering Corporation Viruses expressing chimeric binding proteins
US5693761A (en) 1988-12-28 1997-12-02 Protein Design Labs, Inc. Polynucleotides encoding improved humanized immunoglobulins
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US6417429B1 (en) 1989-10-27 2002-07-09 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US5268164A (en) 1990-04-23 1993-12-07 Alkermes, Inc. Increasing blood-brain barrier permeability with permeabilizer peptides
US5506206A (en) 1990-04-23 1996-04-09 Alkermes, Inc. Increasing blood-brain barrier permeability with permeabilizer peptides
US5112596A (en) 1990-04-23 1992-05-12 Alkermes, Inc. Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability
US5969108A (en) 1990-07-10 1999-10-19 Medical Research Council Methods for producing members of specific binding pairs
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5686416A (en) 1991-04-23 1997-11-11 Alkermes, Inc. Increasing blood-brain barrier permeability with permeabilizer peptides
US6407213B1 (en) 1991-06-14 2002-06-18 Genentech, Inc. Method for making humanized antibodies
US5821337A (en) 1991-06-14 1998-10-13 Genentech, Inc. Immunoglobulin variants
US5648237A (en) 1991-09-19 1997-07-15 Genentech, Inc. Expression of functional antibody fragments
US5885793A (en) 1991-12-02 1999-03-23 Medical Research Council Production of anti-self antibodies from antibody segment repertoires and displayed on phage
US20020025313A1 (en) 1992-07-27 2002-02-28 Micklus Michael J. Targeting of liposomes to the blood-brain barrier
WO1995001937A1 (fr) 1993-07-09 1995-01-19 Association Gradient Procede de traitement de residus de combustion et installation de mise en ×uvre dudit procede
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
WO1997030087A1 (fr) 1996-02-16 1997-08-21 Glaxo Group Limited Preparation d'anticorps glycosyles
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
WO1998058964A1 (fr) 1997-06-24 1998-12-30 Genentech, Inc. Procedes et compositions concernant des glycoproteines galactosylees
WO1999022764A1 (fr) 1997-10-31 1999-05-14 Genentech, Inc. Compositions renfermant des glycoformes de glycoproteine et methodes afferentes
US6602684B1 (en) 1998-04-20 2003-08-05 Glycart Biotechnology Ag Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US7371826B2 (en) 1999-01-15 2008-05-13 Genentech, Inc. Polypeptide variants with altered effector function
US7332581B2 (en) 1999-01-15 2008-02-19 Genentech, Inc. Polypeptide variants with altered effector function
WO2000061739A1 (fr) 1999-04-09 2000-10-19 Kyowa Hakko Kogyo Co., Ltd. Methode de regulation de l'activite d'une molecule immunologiquement fonctionnelle
US6420548B1 (en) 1999-10-04 2002-07-16 Medicago Inc. Method for regulating transcription of foreign genes
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
WO2001029246A1 (fr) 1999-10-19 2001-04-26 Kyowa Hakko Kogyo Co., Ltd. Procede de production d'un polypeptide
US20020038086A1 (en) 2000-07-27 2002-03-28 Hynynen Kullervo H. Blood-brain barrier opening
US7129084B2 (en) 2000-08-03 2006-10-31 Therapeutic Human Polyclonals, Inc. Production of humanized antibodies in transgenic animals
US20020065259A1 (en) 2000-08-30 2002-05-30 Schatzberg Alan F. Glucocorticoid blocking agents for increasing blood-brain barrier permeability
WO2002020565A2 (fr) 2000-09-08 2002-03-14 Universität Zürich Groupes de proteines a domaines de repetition comprenant des modules de repetition
US20030115614A1 (en) 2000-10-06 2003-06-19 Yutaka Kanda Antibody composition-producing cell
US20020164328A1 (en) 2000-10-06 2002-11-07 Toyohide Shinkawa Process for purifying antibody
WO2002031140A1 (fr) 2000-10-06 2002-04-18 Kyowa Hakko Kogyo Co., Ltd. Cellules produisant des compositions d'anticorps
WO2002032925A2 (fr) 2000-10-16 2002-04-25 Phylos, Inc. Echafaudages proteiniques internes pour analogues d'anticorps et autres proteines de liaison
US20030073713A1 (en) 2000-10-30 2003-04-17 Schoenhard Grant L. Inhibitors of ABC drug transporters at the blood-brain barrier
US20040131692A1 (en) 2001-05-05 2004-07-08 Joerg Kreuter Nanoparticles made of protein with coupled apolipoprotein e for penetration of the blood-brain barrier and methods for the production thereof
WO2003011878A2 (fr) 2001-08-03 2003-02-13 Glycart Biotechnology Ag Variants de glycosylation d'anticorps presentant une cytotoxicite cellulaire accrue dependante des anticorps
US20030157108A1 (en) 2001-10-25 2003-08-21 Genentech, Inc. Glycoprotein compositions
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
US20030162695A1 (en) 2002-02-27 2003-08-28 Schatzberg Alan F. Glucocorticoid blocking agents for increasing blood-brain barrier permeability
US20050124533A1 (en) 2002-02-27 2005-06-09 Schatzberg Alan F. Glucocorticoid blocking agents for increasing blood-brain barrier permeability stan-261con
US20040109865A1 (en) 2002-04-09 2004-06-10 Kyowa Hakko Kogyo Co., Ltd. Antibody composition-containing medicament
US20040110282A1 (en) 2002-04-09 2004-06-10 Kyowa Hakko Kogyo Co., Ltd. Cells in which activity of the protein involved in transportation of GDP-fucose is reduced or lost
US20040110704A1 (en) 2002-04-09 2004-06-10 Kyowa Hakko Kogyo Co., Ltd. Cells of which genome is modified
US20040132140A1 (en) 2002-04-09 2004-07-08 Kyowa Hakko Kogyo Co., Ltd. Production process for antibody composition
WO2003084570A1 (fr) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Medicament contenant une composition d'anticorps appropriee au patient souffrant de polymorphisme fc$g(g)riiia
WO2003085119A1 (fr) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Procede d'amelioration de l'activite d'une composition d'anticorps de liaison avec le recepteur fc$g(g) iiia
WO2003085107A1 (fr) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Cellules à génome modifié
WO2004044011A2 (fr) 2002-11-06 2004-05-27 Avidia Research Institute Bibliotheques combinatoires de domaines de monomere
US20040204354A1 (en) 2002-12-03 2004-10-14 Thomas Nelson Artificial low-density lipoprotein carriers for transport of substances across the blood-brain barrier
WO2004056312A2 (fr) 2002-12-16 2004-07-08 Genentech, Inc. Variants d'immunoglobuline et utilisations
US20050260186A1 (en) 2003-03-05 2005-11-24 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US20050089473A1 (en) 2003-09-10 2005-04-28 Cedars-Sinai Medical Center Potassium channel mediated delivery of agents through the blood-brain barrier
WO2005035586A1 (fr) 2003-10-08 2005-04-21 Kyowa Hakko Kogyo Co., Ltd. Composition proteique hybride
WO2005035778A1 (fr) 2003-10-09 2005-04-21 Kyowa Hakko Kogyo Co., Ltd. Procede permettant de produire une composition d'anticorps par inhibition par l'arn de la fonction de $g(a)1,6-fucosyltransferase
WO2005040229A2 (fr) 2003-10-24 2005-05-06 Avidia, Inc. Multimeres et monomeres comprenant des domaines de recepteur de lipoproteines de basse densite de classe a et egf
US20050123546A1 (en) 2003-11-05 2005-06-09 Glycart Biotechnology Ag Antigen binding molecules with increased Fc receptor binding affinity and effector function
WO2005053742A1 (fr) 2003-12-04 2005-06-16 Kyowa Hakko Kogyo Co., Ltd. Medicament contenant une composition a base d'anticorps
WO2005100402A1 (fr) 2004-04-13 2005-10-27 F.Hoffmann-La Roche Ag Anticorps anti-p-selectine
WO2006029879A2 (fr) 2004-09-17 2006-03-23 F.Hoffmann-La Roche Ag Anticorps anti-ox40l
US7521541B2 (en) 2004-09-23 2009-04-21 Genetech Inc. Cysteine engineered antibodies and conjugates
WO2006044908A2 (fr) 2004-10-20 2006-04-27 Genentech, Inc. Formulations d'anticorps
WO2008077546A1 (fr) 2006-12-22 2008-07-03 F. Hoffmann-La Roche Ag Anticorps contre le récepteur du facteur de croissance i de type insuline et leurs utilisations
WO2012020124A1 (fr) 2010-08-12 2012-02-16 Ac Immune S.A. Vaccin obtenu par génie génétique
WO2012055933A1 (fr) 2010-10-26 2012-05-03 Ac Immune S.A. Préparation d'un produit de recombinaison antigénique
WO2013061163A2 (fr) 2011-10-28 2013-05-02 Biogen Idec International Neuroscience Gmbh Molécules de liaison spécifiques de tdp-43
WO2013135588A1 (fr) 2012-03-16 2013-09-19 Covagen Ag Nouvelles molécules de liaison à activité antinéoplasique
WO2019134981A1 (fr) 2018-01-05 2019-07-11 Ac Immune Sa Molécules de liaison de tdp-43 mal-repliées
WO2020234473A1 (fr) 2019-05-23 2020-11-26 Ac Immune Sa Molécules de liaison anti-tdp-43 et leurs utilisations
US20220315648A1 (en) * 2019-05-23 2022-10-06 Ac Immune Sa Anti-TDP-43 Binding Molecules and Uses Thereof
US20230322908A1 (en) * 2020-08-14 2023-10-12 Ac Immune Sa Humanized Anti-TDP-43 Binding Molecules and Uses Thereof
WO2023194565A1 (fr) * 2022-04-08 2023-10-12 Ac Immune Sa Molécules de liaison anti-tdp-43

Non-Patent Citations (104)

* Cited by examiner, † Cited by third party
Title
"Remington: the Science and Practice of Pharmacy", 1995, LIPPINCOTT, WILLIAMS & WILKINS
"Remington's Pharmaceutical Sciences", 1980, MACK PUBLISHING COMPANY
"The Handbook of Pharmaceutical Excipients", 2003, AMERICAN PHARMACEUTICALS ASSOCIATION
ABHINANDAN KRMARTIN ACR: "Analysis and improvements to Kabat and structurally correct numbering of antibody variable domains.", MOL IMMUNOL., vol. 45, 2008, pages 3832 - 9, XP023437109, DOI: 10.1016/j.molimm.2008.05.022
ARAI ET AL.: "TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 351, 2006, pages 602 - 611, XP024925727, DOI: 10.1016/j.bbrc.2006.10.093
BETTS ET AL., MABS, 2018
BETTS ET AL.: "Linear pharmacokinetic parameters for monoclonal antibodies are similar within a species and across different pharmacological targets: A comparison between human, cynomolgus monkey and hFcRn Tg32 transgenic mouse using a population-modeling approach", MABS, vol. 10, 2018
BRETTSCHNEIDER ET AL.: "Stages of pTDP-43 pathology in amyotrophic lateral sclerosis", ANN NEUROL., vol. 74, no. 1, July 2013 (2013-07-01), pages 20 - 38, XP071641043, DOI: 10.1002/ana.23937
BRETTSCHNEIDER J ET AL.: "Spreading of pathology in neurodegenerative diseases: a focus on human studies", NATURE REV. NEUROSCIENCE, 2015, pages 109
BRUGGEMANN, M. ET AL., J. EXP. MED., vol. 166, 1987, pages 1351 - 1361
BURATTIBARALLE: "Nuclear factor TDP-43 can affect selected microRNAlevels", FEBS JOURNAL, vol. 277, 2010, pages 2268 - 2281, XP055081048, DOI: 10.1111/j.1742-4658.2010.07643.x
CHOTHIA CLESK AM: "Canonical structures for the hypervariable regions of immunoglobulins", J MOL BIOL., vol. 196, no. 4, 20 August 1987 (1987-08-20), pages 901 - 17, XP024010426, DOI: 10.1016/0022-2836(87)90412-8
CHOWDHURY, METHODS MOL. BIOL., vol. 207, 2008, pages 179 - 196
CLYNES ET AL., PROC. NAT'LACAD. SCI. USA, vol. 95, 1998, pages 652 - 656
CLYNES ET AL.: "Fc receptors are required in passive and active immunity to melanoma", PROC. NAT'L ACAD. SCI. USA, vol. 95, 1998, pages 652 - 656
COHEN ET AL.: "An acetylation switch controls TDP-43 function and aggregation propensity", NAT COMMUN., vol. 6, 2015, pages 5845
CRAGG, M.S. ET AL.: "Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts", BLOOD, vol. 101, 2003, pages 1045 - 1052, XP002329935, DOI: 10.1182/blood-2002-06-1761
CRAGG, M.S.M.J. GLENNIE: "Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents", BLOOD, vol. 103, 2004, pages 2738 - 2743, XP002465311, DOI: 10.1182/blood-2003-06-2031
CUNNINGHAMWELLS: "High-resolution epitope mapping of hGH-receptor interactions by alanine-scanning mutagenesis", SCIENCE, vol. 244, 1989, pages 1081 - 1085, XP000025308, DOI: 10.1126/science.2471267
CURRENT OPINION IN BIOTECHNOLOGY, vol. 17, 2006, pages 653 - 658
CURRENT OPINION IN BIOTECHNOLOGY, vol. 18, 2007, pages 1 - 10
CURRENT OPINION IN STRUCTURAL BIOLOGY, vol. 7, 1997, pages 463 - 469
DALL' ACQUA ET AL., J IMMUNOL., vol. 169, 2002, pages 5171 - 5180
DALL' ACQUA ET AL.: "Increasing the Affinity of a Human IgG1 for the Neonatal Fc Receptor: Biological Consequences", JOURNAL OF IMMUNOLOGY, vol. 169, no. 9, 2002, pages 5171 - 5180
DIETZ ET AL., J. NEUROCHEM., vol. 104, 2008, pages 757 - 765
EDELMAN, G.M. ET AL.: "The Covalent Structure of an Entire gammaG Immunoglobulin Molecule", PROC. NATL. ACAD. USA, vol. 63, 1969, pages 78 - 85, XP055122293, DOI: 10.1073/pnas.63.1.78
EDWARD B. LEE ET AL., ACTA NEUROPATHOL., vol. 134, no. 1, July 2017 (2017-07-01), pages 65 - 78
EHRENMANN, FRANCOISQUENTIN KAASMARIE-PAULE LEFRANC: "IMGT/3Dstructure-DB and IMGT/DomainGapAlign: a database and a tool for immunoglobulins or antibodies, T cell receptors, MHC, IgSF and MhcSF.", NUCLEIC ACIDS RESEARCH, vol. 38, 2010, XP055247165, DOI: 10.1093/nar/gkp946
FEILER ET AL.: "TDP-43 is intercellularly transmitted across axon Terminals", J. CELL BIOL., vol. 211, no. 4, pages 897 - 911
FENEBERG ET AL.: "Towards a TDP-43-Based Biomarker for ALS and FTLD", MOLECULAR NEUROBIOLOGY, vol. 55, no. 10, 2018, pages 7789 - 7801, XP036585753, DOI: 10.1007/s12035-018-0947-6
GAZZANO-SANTORO ET AL.: "Engineered Antibodies with Increased Activity to Recruit Complement", J. IMMUNOL. METHODS, vol. 202, 1996, pages 163
GERHARDT ET AL.: "Pharmaceutical Codex: Principles and Practice of Pharmaceutics", 1994, PHARMACEUTICAL PRESS, pages: 269 - 315
GERNGROSS: "Advances in the production of human therapeutic proteins in yeasts and filamentous fungi", NAT. BIOTECH., vol. 22, 2004, pages 1409 - 1414, XP037159578, DOI: 10.1038/nbt1028
GILLET, NATURE MED., vol. 248, 2003, pages 589 - 595
GIUDICELLI VCHAUME DBODMER JMILLER WBUSIN CMARSH SBONTROP RMARC LMALIK ALEFRANC MP: "IMGT, the international ImMunoGeneTics database.", NUCLEIC ACIDS RES., vol. 25, no. 1, 1 January 1997 (1997-01-01), pages 206 - 11
GLOVER, COLIN PJALISON S. BIENEMANNDARREN J. HEYWOODA. SIOBHAN COSGRAVEJAMES B. UNEY: "Adenoviral-mediated, high-level, cell-specific transgene expression: a SYN1-WPRE cassette mediates increased transgene expression with no loss of neuron specificity", MOLECULAR THERAPY, vol. 5, no. 5, 2002, pages 509 - 516, XP055729217, DOI: 10.1006/mthe.2002.0588
GOODMANGILMAN: "the Pharmacological Basis of Therapeutics", 1992, MCGRAW HILL
GRAHAM ET AL.: "Characteristics of a human cell line transformed by DNA from human adenovirus type 5", J. GEN VIRAL., vol. 36, 1977, pages 59, XP008153803, DOI: 10.1099/0022-1317-36-1-59
HARLOWLANE: "Using Antibodies: A Laboratory Manual", 1999, COLD SPRING HARBOR LABORATORY PRESS
HASEGAWA ET AL., ANN NEUROL, vol. 64, 2008, pages 60 - 70
HASEGAWA ET AL.: "Phosphorylated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis", ANNALS OF NEUROLOGY, vol. 64, no. 1, 2008, pages 60 - 70, XP009137602
HASEGAWA ET AL.: "Prion-like mechanisms and potential therapeutic targets in neurodegenerative disorders", PHARMACOL THER., vol. 172, April 2017 (2017-04-01), pages 22 - 33, XP029939862, DOI: 10.1016/j.pharmthera.2016.11.010
HELLER, J CELL MOL MED., vol. 00, 2020, pages 1 - 7
HELLSTROM, I ET AL., PROC. NAT'L ACAD. SCI. USA, vol. 82, 1985, pages 1499 - 1502
HELLSTROM, I. ET AL., PROC. NAT'L ACAD. SCI. USA, vol. 83, 1986, pages 7059 - 7063
HELLSTROM, I. ET AL., PROC. NAT'LACAD. SCI. USA, vol. 83, 1986, pages 7059 - 7063
ISHII ET AL.: "Formation and spreading of TDP-43 aggregates in cultured neuronal and glial cells demonstrated by time-lapse imaging", PLOS ONE, vol. 12, no. 6, 2017, pages 0179375
JONES ET AL.: "Replacing the complementarity-determining regions in a human antibody with those from a mouse", NATURE, vol. 321, 1986, pages 522 - 525, XP002949266, DOI: 10.1038/321522a0
JONES ET AL.: "Reshaping human antibodies for therapy", NATURE, vol. 332, 1998, pages 323 - 327
JOSEPHS KA ET AL.: "TDP-43 is a key player in the clinical features associated with Alzheimer's disease", ACTA NEUROPATHOL., vol. 127, no. 6, 2014, pages 811 - 824
KA ET AL.: "Staging TDP-43 pathology in Alzheimer's disease", ACTA NEUROPATHOL., vol. 127, no. 3, 2014, pages 441 - 450
KABAT ET AL.: "Sequences of Proteins of Immunological Interest", 1991, U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, pages: 91 - 3242
KAM ET AL., PROC. NATL. ACAD. SCI. USA, vol. 102, 2005, pages 11600 - 11605
KANDA Y. ET AL., BIOTEEHNOL. BIOENG., vol. 94, no. 4, 2006, pages 680 - 688
KANDA, Y. ET AL., BIOTECHNOL. BIOENG., vol. 94, no. 4, 2006, pages 680 - 688
KASAI ET AL.: "Combined use of CSF NfL and CSF TDP-43 improves diagnostic performance in ALS", ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY, vol. 6, no. 12, 2019, pages 2489 - 2502, XP093282724, DOI: 10.1002/acn3.50943
KOHLER, NATURE, vol. 256, 1975, pages 495
LAGIER-TOURENNE ET AL.: "TDP-43 and FUS/TLS: emerging roles in RNA processing and neurodegeneration", HUMAN MOLECULAR GENETICS, vol. 19, 2010, XP055338929, DOI: 10.1093/hmg/ddq137
LAGIER-TOURENNECLEVELAND: "Rethinking ALS: the FUS about TDP-43", CELL, vol. 136, 2009, pages 1001 - 1004, XP002694640, DOI: 10.1016/j.cell.2009.03.006
LE BER: "Genetics of frontotemporal lobar degeneration: an up-date and diagnosis algorithm", REVUE NEUROLOGIQUE, vol. 169, 2013, pages 811 - 819
LEFRANC MP., IMMUNOL TODAY., vol. 18, no. 11, November 1997 (1997-11-01), pages 509
LI ET AL.: "Optimization of humanized IgGs in glycoengineered Pichia pastoris", NAT. BIOTECH., vol. 24, 2006, pages 210 - 215, XP002493048, DOI: 10.1038/nbt1178
LO, M. ET AL., JOURNAL OF BIOCHEMISTRY, vol. 292, pages 3900 - 3908
LOBUGLIO, PROCEEDINGS OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY ABSTRACT, 1997, pages 1562
MACCALLUM RMMARTIN ACTHORNTON JM, J MOL BIOL., vol. 262, no. 5, 11 October 1996 (1996-10-11), pages 732 - 45
MACKENZIENEUMANN: "Molecular neuropathology of frontotemporal dementia: insights into disease mechanisms from postmortem studies", J. NEUROCHEM., vol. 138, 2016, pages 54 - 70, XP055456980, DOI: 10.1111/jnc.13588
MARROQUIN BELAUNZARAN ET AL., PLOS ONE, vol. 6, no. 4, 2011, pages 18268
MARSCHALL, ANDREA LJSTEFAN DÜBELTHOMAS BOLDICKE: "MAbs", vol. 7, 2015, TAYLOR & FRANCIS, article "Specific in vivo knockdown of protein function by intrabodies"
MATHER ET AL.: "Culture of testicular cells in hormone-supplemented serum-free medium", ANNALS N. Y AEAD. SEI., vol. 383, 1982, pages 44 - 68
MATHER: "Establishment and characterization of two distinct mouse testicular epithelial cell lines", BIOL. REPROD., vol. 23, 1980, pages 243 - 251
MCALEESE ET AL.: "TDP-43 pathology in Alzheimer's disease, dementia with Lewy bodies and ageing", BRAIN PATHOL., vol. 27, no. 4, July 2017 (2017-07-01), pages 472 - 479
MITTAL ET AL., DRUG DELIV., vol. 21, no. 2, 2014, pages 75 - 86
NEUMANN ET AL., ACTA NEUROPATHOL, vol. 117, 2009, pages 137 - 149
NEUMANN ET AL.: "Phosphorylation of S409/410 of TDP-43 is a consistent feature in all sporadic and familial forms of TDP-43 proteinopathies", ACTA NEUROPATHOL., vol. 117, 2009, pages 137 - 149, XP019713359
NEUMANN ET AL.: "Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis", SCIENCE, vol. 314, 2006, pages 130 - 133, XP002534603, DOI: 10.1126/SCIENCE.1134108
NONAKA ET AL.: "Prion-like Properties of Pathological TDP-43 Aggregates from Diseased Brains", CELL REPORTS, vol. 4, 2013, pages 124 - 134
OGANESYAN ET AL., ACTA CRYST., 2008, pages 700 - 704
OKAZAKI ET AL.: "Fucose depletion from human IgG 1 oligosaccharide enhances binding enthalpy and association rate between IgG1 and FcgammaRIIIa", J. MOL. BIOL., vol. 336, 2004, pages 1239 - 1249
PAPANASTASSIOU ET AL., GENE THERAPY, vol. 9, 2002, pages 398 - 406
PETKOVA, S.B. ET AL., INT'L. IMMUNOL., vol. 18, no. 12, 2006, pages 1759 - 1769
PORTA S. ET AL.: "Patient-derived frontotemporal lobar degeneration brain extracts induce formation and spreading of TDP-43 pathology in vivo", NAT. COMM., 2018
PRESTA LG.: "Antibody engineering", CURR OP STRUCT BIOL, vol. 2, 1992, pages 593 - 596, XP024016666, DOI: 10.1016/0959-440X(92)90091-K
PRESTA, CURR. OP. STRUCT. BIOL., vol. 2, 1992, pages 593 - 596
PROTEIN SCIENCE, vol. 15, 2006, pages 14 - 27
RAVETCHKINET, ANNU. REV. IMMUNOL., vol. 9, 1991, pages 457 - 492
REICHMANN ET AL.: "The binding site for C1q on IgG", NATURE, vol. 322, 1988, pages 738 - 327
RIPKA ET AL.: "Two Chinese hamster ovary glycosylation mutants affected in the conversion of GDP-mannose to GDP-fucose.", ARCH. BIOCHEM. BIOPHYS., vol. 249, 1986, pages 533 - 545, XP024759128, DOI: 10.1016/0003-9861(86)90031-7
SAMBROOK ET AL.: "Molecular Cloning: A Laboratory Manual;", 1989, COLD SPRING HARBOR LABORATORY PRESS
SCHLOTHAUER ET AL., PEDS, vol. 29, no. 10, pages 457 - 466
SHEPHERDDEAN: "Monoclonal Antibodies: A Practical Approach", 2000, OXFORD UNIVERSITY PRESS
SHIELDS ET AL.: "High Resolution Mapping of the Binding Site on Human IgG1 for Fc RI, FcγRII, FcγRIII, and FcRn and Design of IgG1 Variants with Improved Binding to the FcyR", J. BIOL. CHEM., vol. 178, no. 2, 2001, pages 6591 - 6604
TICOZZI ET AL., CNS NEUROL. DISORD. DRUG TARGETS., vol. 9, no. 3, 2010, pages 285 - 296
TICOZZI ET AL., PROTEIN AGGREGATION AND DEFECTIVE RNA METABOLISM AS MECHANISMS FOR MOTOR NEURON DAMAGE, vol. 9, no. 3, pages 285 - 296
URLAUB ET AL.: "Isolation of Chinese hamster cell mutants deficient in dihydrofolate reductase activity", PROC. NATL. ACAD. CII. USA, vol. 77, 1980, pages 4216, XP008004784, DOI: 10.1073/pnas.77.7.4216
VERHOEYEN ET AL.: "Reshaping human antibodies: Grafting an antilysozyme activity", SCIENCE, vol. 239, 1988, pages 1534 - 1536, XP002949269, DOI: 10.1126/science.2451287
WANG ACONICELLA AESCHMIDT HBMARTIN EWRHOADS SNREEB AN ET AL.: "A single N-terminal phosphomimic disrupts TDP-43 polymerization, phase separation, and RNA splicing", EMBO J., vol. 37, no. 5, 2018
WANG ET AL.: "TDP-43: an emerging new player in neurodegenerative diseases", TRENDS IN MOLECULAR MEDICINE, vol. 14, no. 11, 2008, pages 479 - 485, XP025585725, DOI: 10.1016/j.molmed.2008.09.001
WARRAICH ET AL.: "TDP-43: a DNA and RNA binding protein with roles in neurodegenerative diseases", THE INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, vol. 42, 2010, pages 1606 - 1609, XP027244005
WORN APLUCKTHUN A: "Stability engineering of antibody single-chain Fv fragments", JOURNAL OF MOLECULAR BIOLOGY, vol. 305, no. 5, 2001, pages 989 - 1010, XP004465987, DOI: 10.1006/jmbi.2000.4265
WRIGHT ET AL.: "Effect of glycosylation on antibody function", TIBTECH, vol. 15, 1997, pages 26 - 32, XP004016809, DOI: 10.1016/S0167-7799(96)10062-7
YAMANE-OHNUKI ET AL.: "Establishment of FUT8 knockout Chinese hamster ovary cells: An ideal host cell line for producing completely defucosylated antibodies with enhanced antibody-dependent cellular cytotoxicity.", BIOTECH. BIOENG., vol. 87, 2004, pages 614, XP002984450, DOI: 10.1002/bit.20151
YE, JIAN ET AL.: "IgBLAST: an immunoglobulin variable domain sequence analysis tool.", NUCLEIC ACIDS RESEARCH, vol. 41, 2013
ZALEVSKY ET AL., NAT BIOTECHNOL., vol. 28, no. 2, 2010, pages 157 - 159
ZALEVSKY, J ET AL.: "Enhanced antibody half-life improves in vivo activity", NAT BIOTECHNOL, vol. 28, no. 2, 2010, pages 157 - 9, XP055308991, DOI: 10.1038/nbt.1601

Similar Documents

Publication Publication Date Title
US20230340090A1 (en) Misfolded TDP-43 Binding Molecules
CN114008073B (zh) 抗tdp-43结合分子及其用途
US20230322908A1 (en) Humanized Anti-TDP-43 Binding Molecules and Uses Thereof
US20250145695A1 (en) Humanized Anti-TDP-43 Binding Molecules and Uses Thereof
AU2023250038A1 (en) Anti-tdp-43 binding molecules
WO2026013218A1 (fr) Vecteurs anti-tdp-43, molécules de liaison et leurs utilisations
US20260043816A1 (en) Anti-TDP-43 Binding Molecules
WO2024184494A1 (fr) Molécules de liaison anti-tdp-43 et leurs utilisations
HK40120986A (zh) 抗tdp-43结合分子
CN118804925A (zh) 人源化抗tdp-43结合分子及其用途
HK40061324B (zh) 抗tdp-43结合分子及其用途
HK40061324A (en) Anti-tdp-43 binding molecules and uses thereof